Hosted on MSN

Quantum BioPharma completes 180-day toxicity dosing for lead MS drug Lucid-MS

An update from Quantum Biopharma ( (TSE:QNTM)) is now available. On December 23, 2025, Quantum BioPharma announced it has completed oral dosing in its 180-day repeated-dose oral toxicity and ...
Seeking Alpha

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and ...
Nasdaq

Quantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND Submission

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...